{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:23:09Z","timestamp":1779114189509,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R306 A18107"],"award-info":[{"award-number":["R306 A18107"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF0071165"],"award-info":[{"award-number":["NNF0071165"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mosaic chromosomal alterations (mCAs) in hematopoietic cells increase mortality and risk of hematological cancers and infections. We investigated the landscape of mCAs and their clinical consequences in 976 patients with multiple myeloma undergoing high-dose chemotherapy and autologous stem cell support (ASCT) with median 6.4 years of follow-up. mCAs were detected in the stem cell harvest product of 158 patients (16.2%). Autosomal aberrations were found in 60 patients (6.1%) and affected all chromosomes. Loss of chromosome X was found in 51 females (12.7%) and loss of chromosome Y in 55 males (9.6%). Overall survival and progression were similar between carriers of autosomal mCAs and non-carriers. In contrast, female patients with loss of the X chromosome had longer overall survival (age-adjusted[a.a.] HR 0.54, 95% CI 0.32\u20130.93, <jats:italic>p<\/jats:italic>\u2009=\u20090.02), lower risk of progression (a.a. HR 0.55, 95% CI 0.35\u20130.87; <jats:italic>p<\/jats:italic>\u2009=\u20090.01), and better post-transplant response (higher degree of complete response (CR) or very good partial response (VGPR)). The reason for this substantial effect is unknown. Additionally, myeloma clones in the stem cell product was confirmed by mCA analysis in the few patients with multiple mCAs (<jats:italic>n<\/jats:italic>\u2009=\u200912 patients). Multiple mCAs conferred inferior overall survival (a.a. HR 2.0, 95% CI 1.02\u20133.84; <jats:italic>p<\/jats:italic>\u2009=\u20090.04) and higher risk of myeloma progression (a.a. HR 3.36, 95% CI 1.67\u20136.81; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), which is presumed to be driven by suspected myeloma contaminants.<\/jats:p>","DOI":"10.1038\/s41375-024-02396-3","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T19:02:26Z","timestamp":1725303746000},"page":"2456-2465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mosaic chromosomal alterations in hematopoietic cells and clinical outcomes in patients with multiple myeloma"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6332-1173","authenticated-orcid":false,"given":"Simon","family":"Husby","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7444-7652","authenticated-orcid":false,"given":"Morten","family":"Tulstrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mads","family":"Harsl\u00f8f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5711-6595","authenticated-orcid":false,"given":"Christian","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Haastrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lene Hyldahl","family":"Ebbesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mette","family":"Klarskov Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4869-8925","authenticated-orcid":false,"given":"Maroulio","family":"Pertesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1816-8106","authenticated-orcid":false,"given":"Christian","family":"Brieghel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9880-5242","authenticated-orcid":false,"given":"Carsten U.","family":"Niemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9943-7007","authenticated-orcid":false,"given":"Agoston Gyula","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels Frost","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Abildgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Vangsted","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1535-9601","authenticated-orcid":false,"given":"Kirsten","family":"Gr\u00f8nb\u00e6k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"key":"2396_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41586-022-04786-y","volume":"606","author":"E Mitchell","year":"2022","unstructured":"Mitchell E, Spencer Chapman M, Williams N, Dawson KJ, Mende N, Calderbank EF, et al. Clonal dynamics of haematopoiesis across the human lifespan. Nature. 2022;606:343\u201350.","journal-title":"Nature"},{"key":"2396_CR2","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/s41586-018-0321-x","volume":"559","author":"P-R Loh","year":"2018","unstructured":"Loh P-R, Genovese G, Handsaker RE, Finucane HK, Reshef YA, Palamara PF, et al. Insights into clonal haematopoiesis from 8342 mosaic chromosomal alterations. Nature. 2018;559:350\u20135.","journal-title":"Nature"},{"key":"2396_CR3","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/s41591-021-01371-0","volume":"27","author":"SM Zekavat","year":"2021","unstructured":"Zekavat SM, Lin S-H, Bick AG, Liu A, Paruchuri K, Wang C, et al. Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection. Nat Med. 2021;27:1012\u201324.","journal-title":"Nat Med"},{"key":"2396_CR4","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/2767-9764.CRC-23-0093","volume":"3","author":"TH Mouhieddine","year":"2023","unstructured":"Mouhieddine TH, Nzerem C, Redd R, Dunford A, Leventhal M, Sklavenitis-Pistofidis R, et al. Clinical outcomes and evolution of clonal hematopoiesis in patients with newly diagnosed multiple myeloma. Cancer Res Commun. 2023;3:2560\u201371.","journal-title":"Cancer Res Commun"},{"key":"2396_CR5","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1038\/s41375-018-0208-8","volume":"32","author":"S Chitre","year":"2018","unstructured":"Chitre S, St\u00f6lzel F, Cuthill K, Streetly M, Graham C, Dill C, et al. Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation. Leukemia. 2018;32:2020\u20134.","journal-title":"Leukemia"},{"key":"2396_CR6","doi-asserted-by":"publisher","first-page":"E157","DOI":"10.1002\/ajh.26125","volume":"96","author":"K Wudhikarn","year":"2021","unstructured":"Wudhikarn K, Padrnos L, Lasho T, LaPlant B, Kumar S, Dispenzieri A, et al. Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy. Am J Hematol. 2021;96:E157\u201362.","journal-title":"Am J Hematol"},{"key":"2396_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16805-5","volume":"11","author":"TH Mouhieddine","year":"2020","unstructured":"Mouhieddine TH, Sperling AS, Redd R, Park J, Leventhal M, Gibson CJ, et al. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020;11:2996.","journal-title":"Nat Commun"},{"key":"2396_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04989-w","volume":"9","author":"M Went","year":"2018","unstructured":"Went M, Sud A, F\u00f6rsti A, Halvarsson B-M, Weinhold N, Kimber S, et al. Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nat Commun. 2018;9:3707.","journal-title":"Nat Commun"},{"key":"2396_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00468-6","volume":"11","author":"L Duran-Lozano","year":"2021","unstructured":"Duran-Lozano L, Thorleifsson G, Lopez de Lapuente Portilla A, Niroula A, Went M, Thodberg M, et al. Germline variants at SOHLH2 influence multiple myeloma risk. Blood Cancer J. 2021;11:76.","journal-title":"Blood Cancer J"},{"key":"2396_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13225-y","volume":"10","author":"O Delaneau","year":"2019","unstructured":"Delaneau O, Zagury J-F, Robinson MR, Marchini JL, Dermitzakis ET. Accurate, scalable and integrative haplotype estimation. Nat Commun. 2019;10:5436.","journal-title":"Nat Commun"},{"key":"2396_CR11","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41586-020-2430-6","volume":"584","author":"P-R Loh","year":"2020","unstructured":"Loh P-R, Genovese G, McCarroll SA. Monogenic and polygenic inheritance become instruments for clonal selection. Nature. 2020;584:136\u201341.","journal-title":"Nature"},{"key":"2396_CR12","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-021-03894-5","volume":"597","author":"R Bentham","year":"2021","unstructured":"Bentham R, Litchfield K, Watkins TBK, Lim EL, Rosenthal R, Mart\u00ednez-Ruiz C, et al. Using DNA sequencing data to quantify T cell fraction and therapy response. Nature. 2021;597:555\u201360.","journal-title":"Nature"},{"key":"2396_CR13","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/ijc.22411","volume":"120","author":"A Vangsted","year":"2007","unstructured":"Vangsted A, Gimsing P, Klausen TW, Nex\u00f8 BA, Wallin H, Andersen P, et al. Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation. Int J Cancer. 2007;120:1036\u201345.","journal-title":"Int J Cancer"},{"key":"2396_CR14","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2147\/CLEP.S99463","volume":"8","author":"P Gimsing","year":"2016","unstructured":"Gimsing P, Holmstr\u00f6m MO, Klausen TW, Andersen NF, Gregersen H, Pedersen RS, et al. The Danish National Multiple myeloma registry. Clin Epidemiol. 2016;8:583\u20137.","journal-title":"Clin Epidemiol"},{"key":"2396_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1177\/1403494811401482","volume":"39","author":"E Lynge","year":"2011","unstructured":"Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 2011;39:30\u20133.","journal-title":"Scand J Public Health"},{"key":"2396_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1600-0609.2010.01465.x","volume":"85","author":"AJ Vangsted","year":"2010","unstructured":"Vangsted AJ, Klausen TW, Andersen NF, Abildgaard N, Gang AO, Gregersen H, et al. Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004. Eur J Haematol. 2010;85:209\u201316.","journal-title":"Eur J Haematol"},{"key":"2396_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/ejh.13707","volume":"108","author":"CH Blimark","year":"2022","unstructured":"Blimark CH, Vangsted AJ, Klausen TW, Gregersen H, Szabo AG, Hermansen E, et al. Outcome data from > 10,000 multiple myeloma patients in the Danish and Swedish national registries. Eur J Haematol. 2022;108:99\u2013108.","journal-title":"Eur J Haematol"},{"key":"2396_CR18","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127:2955\u201362.","journal-title":"Blood"},{"key":"2396_CR19","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/bmt.2016.74","volume":"51","author":"S Wuill\u00e8me","year":"2016","unstructured":"Wuill\u00e8me S, Lok A, Robillard N, Dupuis P, Stocco V, Mign\u00e9 H, et al. Assessment of tumoral plasma cells in apheresis products for autologous stem cell transplantation in multiple myeloma. Bone Marrow Transpl. 2016;51:1143\u20135.","journal-title":"Bone Marrow Transpl"},{"key":"2396_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00842-6","volume":"13","author":"O Pasvolsky","year":"2023","unstructured":"Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi AH, et al. Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood Cancer J. 2023;13:68.","journal-title":"Blood Cancer J"},{"key":"2396_CR21","doi-asserted-by":"publisher","unstructured":"Kostopoulos IV, Eleutherakis-Papaiakovou E, Rousakis P, Ntanasis-Stathopoulos I, Panteli C, Orologas-Stavrou N, et al. Aberrant plasma cell contamination of peripheral blood stem cell autografts, assessed by next-generation flow cytometry, is a negative predictor for deep response post autologous transplantation in multiple myeloma; a prospective study in 199 patients. Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13164047.","DOI":"10.3390\/cancers13164047"},{"key":"2396_CR22","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","volume":"132","author":"BA Walker","year":"2018","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018;132:587\u201397.","journal-title":"Blood"},{"key":"2396_CR23","doi-asserted-by":"publisher","unstructured":"Sperling AS, Guerra VA, Kennedy JA, Yan Y, Hsu JI, Wang F, et al. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood. 2022. https:\/\/doi.org\/10.1182\/blood.2021014956.","DOI":"10.1182\/blood.2021014956"},{"key":"2396_CR24","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s41591-021-01411-9","volume":"27","author":"R Saiki","year":"2021","unstructured":"Saiki R, Momozawa Y, Nannya Y, Nakagawa MM, Ochi Y, Yoshizato T, et al. Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis. Nat Med. 2021;27:1239\u201349.","journal-title":"Nat Med"},{"key":"2396_CR25","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-020-2426-2","volume":"584","author":"C Terao","year":"2020","unstructured":"Terao C, Suzuki A, Momozawa Y, Akiyama M, Ishigaki K, Yamamoto K, et al. Chromosomal alterations among age-related haematopoietic clones in Japan. Nature. 2020;584:130\u20135.","journal-title":"Nature"},{"key":"2396_CR26","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1200\/JCO.23.01277","volume":"42","author":"F Maura","year":"2024","unstructured":"Maura F, Rajanna AR, Ziccheddu B, Poos AM, Derkach A, Maclachlan K, et al. Genomic classification and individualized prognosis in multiple myeloma. J Clin Oncol. 2024;42:1229\u201340.","journal-title":"J Clin Oncol"},{"key":"2396_CR27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1182\/blood-2004-12-4931","volume":"106","author":"AA Jungbluth","year":"2005","unstructured":"Jungbluth AA, Ely S, DiLiberto M, Niesvizky R, Williamson B, Frosina D, et al. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3\/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood. 2005;106:167\u201374.","journal-title":"Blood"},{"key":"2396_CR28","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3324\/haematol.2010.037978","volume":"96","author":"M van Duin","year":"2011","unstructured":"van Duin M, Broyl A, de Knegt Y, Goldschmidt H, Richardson PG, Hop WCJ, et al. Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. Haematologica. 2011;96:1662\u20139.","journal-title":"Haematologica"},{"key":"2396_CR29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.mce.2011.06.012","volume":"340","author":"A Purohit","year":"2011","unstructured":"Purohit A, Woo LWL, Potter BVL. Steroid sulfatase: a pivotal player in estrogen synthesis and metabolism. Mol Cell Endocrinol. 2011;340:154\u201360.","journal-title":"Mol Cell Endocrinol"},{"key":"2396_CR30","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1080\/10428194.2018.1538511","volume":"60","author":"M Ozerova","year":"2019","unstructured":"Ozerova M, Nefedova Y. Estrogen promotes multiple myeloma through enhancing the immunosuppressive activity of MDSC. Leuk Lymphoma. 2019;60:1557\u201362.","journal-title":"Leuk Lymphoma"},{"key":"2396_CR31","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1182\/blood.V92.5.1749","volume":"92","author":"SP Treon","year":"1998","unstructured":"Treon SP, Teoh G, Urashima M, Ogata A, Chauhan D, Webb IJ, et al. Anti-estrogens induce apoptosis of multiple myeloma cells. Blood. 1998;92:1749\u201357.","journal-title":"Blood"},{"key":"2396_CR32","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/ng.2966","volume":"46","author":"LA Forsberg","year":"2014","unstructured":"Forsberg LA, Rasi C, Malmqvist N, Davies H, Pasupulati S, Pakalapati G, et al. Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. Nat Genet. 2014;46:624\u20138.","journal-title":"Nat Genet"},{"key":"2396_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-30759-1","volume":"8","author":"E Loftfield","year":"2018","unstructured":"Loftfield E, Zhou W, Graubard BI, Yeager M, Chanock SJ, Freedman ND, et al. Predictors of mosaic chromosome Y loss and associations with mortality in the UK Biobank. Sci Rep. 2018;8:12316.","journal-title":"Sci Rep"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02396-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02396-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02396-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T13:53:22Z","timestamp":1730296402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02396-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["2396"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02396-3","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,2]]},"assertion":[{"value":"5 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CUN has received research grants and\/or consultancy fees from AstraZeneca, Abbvie, Janssen, Takeda, Octapharma, CSL Behring, Lilly, Beigene and Genmab. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}